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ABBREVIATIONS 
 
ACE angiotensin converting enzyme     
AF atrial fibrillation 
AFL atrial flutter 
APD action potential duration 
ARVC arrhythmogenic right ventricular cardiomyopathy 
AT atrial tachycardia 
AVNA atrio-ventricular node ablation 
AVNRT atrio-ventricular nodal re-entry tachycardia 
AVRT atrio-ventricular re-entry tachycardia 
bpm beats per minute 
Ca Calcium 
CMO Cardiomyopathy 
DCMO  dilated cardiomyopathy 
ECG electrocardiogram 
ERP effective refractory period 
HCM hypertrophic cardiomyopathy 
LA left atrial 
LAH left atrial hypertrophy 
LBBB left bundle branch block 
LV left ventricular 
LVEF left ventricular jection fraction 
LVH left ventricular hypertrophy 
LVIDd left ventricular internal diameter in diastole 
LVIDs left ventricular internal diameter in systole 
MR mitral regurgitation 
MRI magnetic resonance imaging 
NYHA New York Heart Association  
PJRT  permanent junctional reciprocating tachycardia 
PPM permanent pacemaker 
PVC premature ventricular complex 
PVI pulmonary vein isolation 
RAAS renin-angiotensin system 
RBBB right bundle branch block 
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ROC  receiver operating curve 
RVOT right ventricular outflow tract  
RV right ventricular 
Rx Treatment 
TIC tachycardia-induced cardiomyopathy 
VPC ventricular premature complex 
VT  ventricular tachycardia 
WPW Wolff-Parkinson-White 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
ABSTRACT 
 
Introduction 
Tachycardia–induced cardiomyopathy (TIC) is a reversible cause of LV systolic dysfunction 
that can complicate any supraventricular or ventricular tachyarrhythmia.  The aim of this 
study was to characterise the clinical, electrocardiographic and echocardiographic features 
and long-term outcome of patients with TIC. 
 
Methods 
A retrospective study of patients with a diagnosis of TIC at our institution was performed.  
Pure and impure TIC patients were included in this study if the LVEF at presentation was 
<50% with an improvement of symptoms and LVEF >=5% after control of the causative 
tachycardia.  Clinical, electrocardiographic and echocardiographic data of patients with TIC 
were obtained from clinic records.  Twenty-five pure TIC patients were compared to a control 
group of 25 DCMO patients matched for age, sex and LVEF.  Seventeen pure TIC patients 
who had recovered LV function after control of the tachycardia were compared to 17 control 
patients with normal echocardiograms matched for age and LVEF. 
 
Results 
Thirty-three patients with pure TIC were identified.  There were 25 males and 8 females with 
a median age of 44 (30-62) years.  The causes of pure TIC were AF (n=20), AFL (n=7), AT 
(n=4), AVNRT (n=1) and fascicular VT (n=1).  Twelve patients with impure TIC were 
identified.  There were 9 males and 3 females with a median age of 39 (23-59) years.  The 
nature of the underlying structural heart disease in the impure TIC group was hypertension 
(n=3), viral myocarditis (n=2), valvular heart disease (n=3), ischaemic heart disease (n=2),  
patent ductus arteriosus (n=1) and peripartum cardiomyopathy (n=1).  
Compared to patients with pure TIC, patients with impure TIC had shorter durations of 
dyspnoea (p=0.04) and more clinical signs of heart failure at presentation (p=0.003). 
Patients with impure TIC displayed more electrocardiographic features of underlying 
structural heart disease [LA hypertrophy (p=0.05), LV hypertrophy (p<0.001) and larger RV6 
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voltages (p=0.04)].  There were no significant differences in echocardiographic features 
between the 2 groups.   
Compared to patients with DCMO, pure TIC patients were less symptomatic by NYHA class 
(p=0.02), had fewer clinical signs of heart failure (p=0.007) and were more likely to report 
palpitations (p=0.007) at presentation.  Electrocardiographically, pure TIC patients had less 
Q waves (p=0.002), LV hypertrophy (p=0.004), repolarization abnormalities (p=0.048) and 
shorter QRS durations (p=0.024).  Echocardiographically, pure TIC patients had significantly 
smaller LVIDd (p<0.001), LVIDs (p=0.001) and LA dimensions (p=0.048) compared to 
DCMO patients at presentation.   
In 6 patients who had a preserved LVEF documented prior to deterioration, LV dysfunction 
developed over a mean period of 6 (range: 3 to 15) months.  The mean LVEF improved 
significantly from 32.4+/-9.5% to 53.2+/-10.5% (p<0.001) in the pure TIC group.  Both the 
LVIDd (p=0.004) and LVIDs (p=0.001) dimensions improved significantly post treatment.  
The mean LVEF improved significantly from 29.2+/-10.0% to 55.0+/-9.9% in the impure TIC 
group (p<0.001).  Patients with pure TIC had a trend towards increased residual LVIDd 
dimensions compared to a control group of normal echocardiograms indicating a persistence 
of adverse LV remodelling late after control of the causative tachycardia (p=0.06).  Maximal 
recovery of LV function was usually noted by 3 to 6 months.  In 6 patients, a slower rate of 
recovery of LV function (over 6 to 12 months) was observed with lenient rate control (n=4) 
and with severe (LVEF < 20%) LV dysfunction (n=2).  The only predictor of partial recovery 
of LV function was a longer QRS duration (p=0.04).  Recurrent tachycardia occurred in 3 
patients which resulted in a precipitous decline in LVEF.   
  
Conclusions 
This study is the first to compare features of pure and impure TIC.  We found that impure 
TIC may develop more quickly than pure TIC as impure TIC patients have a shorter duration 
and more severe symptoms at presentation which suggests that underlying structural heart 
disease is a risk factor in the pathogenesis of TIC.  Patients with pure TIC have shorter QRS 
durations, less LVH, Q waves and repolarization abnormalities at presentation compared to 
DCMO patients.  TIC patients tend to have smaller LVIDd dimensions at presentation and 
have persistence of adverse LV remodelling as characterised by persistent enlargement of  
LVIDd dimensions at late follow-up.  Patients who have larger LVIDd dimensions at 
presentation tended to have larger LVIDd dimensions at late follow-up, identifying a 
subgroup of patients where careful follow-up is required.  This study confirms that maximal 
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improvement of LV function generally occurs by 3 to 6 months.  However, we noted slower 
improvement in LV function over 12 months in patients who had severe LV dysfunction and 
in patients with AF who had lenient heart rate control.  The only predictor of LV improvement 
was a shorter QRS duration at presentation.  We managed to identify 45 patients with this 
condition over  a 15 year period, suggesting that this condition is frequently under-diagnosed 
and missed.   
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INTRODUCTION 
 
TIC is an important reversible cause of CMO and heart failure.  Until recently TIC was 
considered to be a rare cause of reversible LV dysfunction [1].  However, over the past few 
years there have been several publications that have established that this disease is much 
more prevalent than once thought [2, 3].   
In the first report of TIC published in 1949, Phillips and Levine concluded that “auricular 
fibrillation per se may produce cardiac dilatation and progressive congestive heart 
failure...”[4].  Since that initial description, virtually any supraventricular or ventricular 
tachycardia including frequent premature ventricular ectopy, have been implicated in the 
pathogenesis of TIC.  However, most reports of TIC have been isolated case reports or 
small retrospective cohorts comprising less than 20 to 30 patients. 
LV dysfunction may either develop in the setting of no underlying structural heart disease, 
so-called “pure” TIC or in the setting of pre-existing structural heart disease, so called 
“impure” TIC [5].  TIC studies have mostly enrolled pure TIC patients and have excluded 
patients with impure TIC.  However, impure TIC is probably more common than pure TIC, 
but less well investigated and reported in the literature.   
Interestingly, not all patients exposed to a chronic tachycardia will develop TIC.  In the 
individual patient, the complex interplay of substrate-related factors (genetics and structural 
heart disease) and tachycardia-related factors (rate, duration and nature of the tachycardia) 
determine the development of TIC.  The presenting clinical, electrocardiographic and 
echocardiographic features of TIC have not been well described.  At presentation, TIC may 
be indistinguishable from a DCMO with a secondary tachycardia – the so-called “chicken-
egg dilemma” [6].  The diagnosis of TIC is usually a retrospective diagnosis made after 
control of the tachycardia leads to improvement in LV function.  Factors influencing the rate 
and extent of recovery of LV function are poorly understood.  Lastly, the long-term outcome 
and prognosis of patients with TIC have not been well defined. 
In order to answer some of these questions, we conducted a retrospective study of TIC at 
our institution.  In this study, we report the clinical, electrocardiographic and 
echocardiographic features of a relatively large cohort of 45 patients with pure and impure 
TIC.  One of the aims of this study was to identify clinical, electrocardiographic and 
echocardiographic features that could help the clinician recognise this condition by 
comparing 25 patients with pure TIC to 25 patients with DCMO.  We report on the response 
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to treatment and compare 17 patients who had normalised LV function after control of the 
tachycardia with 17 control patients with normal echocardiograms to assess for persistence 
of adverse LV remodelling.  We report on the long-term outcome and prognosis of these 
patients.  Finally, we present a literature review of the topic. 
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METHODS 
 
Study  
We conducted a retrospective study of patients with a diagnosis of TIC who presented to the 
cardiac clinic at Groote Schuur Hospital, Cape Town, South Africa between 1994 and 2009. 
The study protocol was approved by the University of Cape Town’s Ethics Committee.  
 
Study population 
We included patients with a diagnosis of TIC if the presenting LVEF was <50% and there 
was an LVEF improvement of >=5% after rate or rhythm control of the tachycardia with 
medical or ablative therapy.  Patients were included in the pure TIC group if no underlying 
structural heart disease could be identified.  Patients with tachycardia-induced LV 
dysfunction with underlying structural heart disease were included in the impure TIC group 
and analyzed separately.  The cohort of 33 patients with pure TIC was compared to 12 
patients with impure TIC.  We were able to compare 25 patients with pure TIC with 25 
control patients with DCMO (matched for age, sex and presenting LVEF) with regards to 
clinical, electrocardiographic and echocardiographic parameters.  The DCMO patients were 
obtained from the CMO registry at Groote Schuur Hospital (unpublished data).  To assess 
for persistence of adverse LV remodelling after recovery of LV function, the last available 
echocardiograms of 17 pure TIC patients who had recovered LV function (post treatment 
LVEF >=50%) were compared to 17 normal echocardiograms matched for age and LVEF. 
For the purposes of this paper, TIC includes pure and impure TIC unless otherwise 
specified. 
 
Data collection 
Retrospective data collection included clinical, electrocardiographic and echocardiographic 
characteristics and long-term follow-up of patients diagnosed with pure or impure TIC and 
matched DCMO controls.  Patients diagnosed with TIC during the course of this study were 
followed prospectively.  Patients’ clinical records were extensively reviewed.  All previous 
ECGs of patients with TIC were retrieved from an ECG archival system (MUSE CV system) 
and reviewed to calculate mean heart rate prior to the diagnosis of TIC.  All 24-hour Holter 
monitors performed prior to the diagnosis of TIC were analysed to determine mean and 
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maximum heart rates during a 24 hour period.  Transthoracic echocardiography was 
performed to measure LVEF, LVIDd, LVIDs, LA size and to quantitate the severity of MR 
using standard M-mode or modified Simpson’s method according to the recommendations of 
the American Society of Echocardiography.  Radionucleotide imaging that calculated LVEF 
was used when available.  Serial echocardiograms, if available, were reviewed in patients 
with TIC to assess the rate and magnitude of LV function improvement.  All subsequent 
visits were reviewed and recurrences of any tachycardias were documented.  Patients who 
had been discharged to follow-up or who were no longer attending the cardiac clinic were 
telephonically contacted.   
 
Treatment 
The choice of treatment of the causative tachycardia was at the discretion of the attending 
cardiologist.  Generally, in patients with AF, rate control using AV nodal blockers (Beta-
blockers, Ca-channel blockers), anti-arrhythmic drugs or digoxin was initially preferred. 
Patients with drug-resistant AF who continued to have poor rate control despite the above 
treatment, were referred for AVNA and PPM implantation.  Catheter ablation was considered 
first-line therapy for certain arrhythmias (AFL, AT, AVNRT, AVRT and fascicular VT). 
 
Statistical analysis 
Results are expressed as mean (standard deviation) or median (interquartile range).  Clinical 
and socio-demographic characteristics of groups studied were compared using the t-test, 2 
test, Mann-Whitney test or Wilcoxon signed rank test, whichever was appropriate.  A p-value 
of <0.05 was considered significant.  Non-parametric tests were used due to the non-
normality of some of the variables studied.  Receiver operating characteristic (ROC) curves 
were plotted to examine the diagnostic utility of some variables, which was expressed as an 
area under the curve and measured using the C-statistic.  Data were analysed using SPSS 
version 17 (Chicago, Illinois; 2009).  
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RESULTS 
 
Patient demographics, clinical features, investigations, treatment and long-term outcomes of 
the pure and impure TIC cohort are displayed in Table 1.  
 
Clinical, electrocardiographic and echocardiographic features of pure and impure TIC  
The presenting clinical, electrocardiographic and echocardiographic features of the pure and 
impure TIC cohort are compared in Tables 2A, 2B and 2C respectively.  The arrhythmic 
causes of pure and impure TIC are listed in Table 3.   
 
Pure TIC 
The pure TIC cohort consisted of 33 patients (25 males, 8 females).  The median age was 
44 (30-62) years with marked male predominance (76%).  Twenty-one (64%) patients 
presented with severe effort intolerance (NYHA class III, IV).  The median duration of 
dyspnoea and palpitations prior to presentation was 2 (0.6-7.5) months and 7 (1.3-51.0) 
months respectively.  The arrhythmic causes were AF (n=20), AFL (n=7), AT (n=4), AVNRT 
(n=1) and fascicular VT (n=1).  The most common ECG abnormalities were repolarization 
abnormalities (55%) followed by LV hypertrophy (12%) and LA hypertrophy (9%).  Q waves, 
LBBB and RBBB were seen in less than 7% of presenting ECGs.  The mean LVEF at 
presentation was 32.4+/-9.5%.  The mean LVIDd and LVIDs dimensions were 5.7+/-0.7cm 
and 4.8+/-0.8cm respectively.  The mean LA size was 4.2+/-1.0cm. 
 
Impure TIC 
The impure TIC cohort consisted of 12 patients (9 males, 3 females).  The nature of the 
underlying structural heart disease was hypertension (n=3), viral myocarditis (n=2), valvular 
heart disease (n=3), ischaemic heart disease (n=2),  patent ductus arteriosus (n=1) and 
peripartum cardiomyopathy (n=1).  The median age was 39 (23-59) years with marked male 
predominance (75%).  Eleven (92%) patients presented with severe effort intolerance 
(NYHA III, IV).  The median duration of dyspnoea and palpitations prior to presentation was 
0.5 (0.2-2.0) months and 3 (0.6-4.5) months respectively.  The arrhythmic causes were AF 
(n= 5), AFL (n= 4), AVNRT (n=2) and AVRT (n=1).  The most common ECG abnormalities 
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were repolarization abnormalities (70%) and LV hypertrophy (70%).  The mean LVEF at 
presentation was 29.2+/-1.0%.  The mean LVIDd and LVIDs dimensions were 5.7+/-1.0cm 
and 4.8+/-0.8cm respectively.  The mean LA size was 4.8+/-1.5cm.   
 
Comparison between pure and impure TIC 
Compared to patients with pure TIC, patients with impure TIC had shorter durations of 
dyspnoea (p=0.04) and more clinical signs of heart failure at presentation (p=0.003). 
Patients with impure TIC displayed more ECG features of underlying structural heart disease 
[LA hypertrophy (p=0.05), LV hypertrophy (p<0.001) and larger RV6 voltages (p=0.04)].  
There were no significant differences in presenting echocardiographic features between the 
2 groups. 
 
Comparison of clinical, electrocardiographic and echocardiographic features of pure 
TIC and DCMO matched for age, sex and LVEF 
In order to identify characteristics that may be useful to differentiate between pure TIC and 
DCMO at presentation, we compared 25 pure TIC patients with 25 DCMO patients matched 
for age, sex and LVEF.  The clinical, electrocardiographic and echocardiographic features of 
the 2 groups are displayed in Table 4.  
Clinically, pure TIC patients were less symptomatic by NYHA class (p=0.02), had fewer 
clinical signs of heart failure (p=0.007) and were more likely to report palpitations (p=0.007) t 
presentation.  Electrocardiographically, TIC patients had less Q waves (p=0.002), LV 
hypertrophy (p=0.004), repolarization abnormalities (p=0.048) and shorter QRS durations 
(p=0.024).  Six DCMO patients had underlying paroxysmal or permanent AF.  There were no 
significant differences in the prevalence of LA enlargement, LBBB, RBBB, RV6 voltage or 
RV6/RVmax ratio between the 2 groups.  Echocardiographically, pure TIC patients had 
significantly smaller LVIDd (p<0.001), LVIDs (p=0.001) and LA dimensions (p=0.048) 
compared to DCMO patients at presentation.   
Despite significant differences in LVIDd dimensions and QRS duration between the 2 
groups, we could not identify any LVIDd dimension or QRS duration that could predict a 
diagnosis of pure TIC with a high sensitivity and specificity (Graph 1, Graph 2). 
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Rate of deterioration of left ventricular function 
The rate of deterioration of LV function after uncontrolled tachycardia has not been well 
defined, as most patients will not have had an LVEF documented prior to deterioration.  We 
identified 6 patients who had preserved LV function documented prior to the development of 
TIC.  We noted that LV function in these 6 patients deteriorated over a mean period of 6 
months (range: 3 to 15 months).  Table 5 displays the causative tachycardia, the average 
ventricular rate during the tachycardia prior to the diagnosis of TIC, LVEF before TIC, TIC 
LVEF, medication used and the time period of deterioration. 
 
Pre and post-treatment echocardiographic parameters of pure and impure TIC 
The pre and post-treatment echocardiographic parameters of pure and impure TIC are 
displayed in Table 6.  In the pure TIC group, the mean LVEF improved significantly from 
32.4+/-9.5% to 53.2+/-10.5% (p<0.001).  Both the LVIDd (p=0.004) and LVIDs (p=0.001) 
dimensions improved significantly post treatment.  There was no significant decrease in LA 
size pre and post-treatment.  In the impure TIC group, the mean LVEF improved significantly 
from 29.2+/-10.0% to 55.0+/-9.9% (p<0.001).  The LVIDs dimension (p=0.04), but not the 
LVIDd dimension, improved significantly post treatment.  There was no change in LA size 
pre and post-treatment in the impure TIC group.  
 
Rate of improvement of left ventricular function 
We identified variable rates of LV improvement after control of the tachycardia.  Thirteen 
pure TIC patients had at least 3 echocardiograms performed - at initial diagnosis, when 
improvement of LV function was documented, and at last available follow-up.  In 7 (54%) 
patients, maximal recovery was noted early within the first 3 to 6 months after control of 
the tachycardia (Graph 3, Group A).  However, in 6 (46%) patients, maximal LV 
improvement occurred late after 6 months with improvement seen even after a year 
(Graph 4, Group B).  Of these 6 patients, 2 patients had LVEF <20% and 4 patients had 
lenient heart rate control as defined by the AFFIRM trial [8] criteria (resting heart rate 
>=80bpm) (Table 7). 
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Comparison of post-treatment echocardiographic parameters of pure TIC with 
complete LV improvement and normal controls matched for age and LVEF  
Seventeen patients with pure TIC who had an improvement of LVEF to >50% after control of 
the tachycardia were compared to 17 control patients with normal echocardiograms matched 
for age and LVEF (Table 8).  Patients with pure TIC had a trend towards increased residual 
LVIDd dimensions compared to the control group indicating a persistence of adverse LV 
remodelling late after control of the causative tachycardia (p=0.06).  There were no 
significant differences between the LVIDs and LA dimensions between the 2 groups. 
 
Comparison of pure TIC patients with complete versus partial LV improvement 
We compared 22 pure TIC patients who had complete LV improvement (post-treatment 
LVEF >=50%) with 10 pure TIC patients who had partial LV improvement (post-treatment 
LVEF <50%) after control of the causative tachycardia to identify predictors of improvement 
(Table 9).  The only predictor of partial improvement was a longer QRS duration at initial 
presentation which was significantly longer in the group who had partial improvement of LV 
function (p=0.04). 
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DISCUSSION AND LITERATURE REVIEW  
 
Introduction 
 
The terms tachycardia-induced cardiomyopathy, tachycardia-mediated cardiomyopathy, 
tachycardia-related cardiomyopathy or tachycardiomyopathy refer to a non-familial cause of 
DCMO characterised by an impairment of LV systolic dysfunction secondary to a chronic 
tachycardia or frequent ventricular ectopy which is partially or completely reversible after 
control of heart rate [7].  Isolated right ventricular dysfunction secondary to ventricular 
tachycardia has also been reported [8].  According to the number of terms indexed in 
MEDLINE, the most frequently used term is tachycardia-induced cardiomyopathy. 
 
Subtypes  
TIC can be divided into 2 types:  
1. “Pure” TIC when a chronic tachycardia results in LV dysfunction in an otherwise normal 
heart                                  
                                                                                                                     
2. “Impure” TIC when a chronic tachycardia results in LV dysfunction in a patient with 
underlying structural heart disease 
Since this classification was first proposed, it has not been widely adopted [5].   
 
TIC study definitions 
No universal definition of TIC exists.  Previous studies have used variable TIC definitions.  
Some studies included patients with a presenting LVEF <=40-45% [9-11].  Other studies 
have included patients up to LVEF <=50% [12-14].  While most studies have required 
symptomatic and LV function improvement after control of the tachycardia to make a 
diagnosis of TIC, the magnitude of  improvement of  LVEF required to be included in studies 
has been variable ranging from improvement in LVEF of at least 5% [10] to 15% [9, 11] or an 
absolute post-treatment LVEF >=50% [13].  Although impure TIC may be more common 
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than pure TIC, few studies have reported on this entity [15].  In this study, we included all 
patients with a diagnosis of TIC with a LVEF <50% at presentation with an improvement in 
symptoms and an LVEF of at least 5% after control of the tachycardia.  
 
Prevalence 
The prevalence of TIC is unknown.  One study found the entity to be rare cause of DCMO – 
out of 673 consecutive cases of DCMO, tachycardia was identified as a cause in 1 patient 
[1].  In a large cohort of unexplained cardiomyopathy and in a prospective registry of 
cardiovascular disease in Soweto, South Africa, TIC was not reported as a cause of 
unexplained cardiomyopathy or heart failure in any of the patients [16, 17].  However, 
studies of drug-refractory AF and LV dysfunction referred for radiofrequency ablation 
suggest that TIC may have a prevalence rate of 11-30% [3, 18].  The above data suggests 
that a diagnosis of TIC is frequently under-recognised and missed. 
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Pathogenesis of TIC  
 
Understanding of the pathogenesis of TIC comes mainly from animal models.  Rapid, 
sustained atrial or ventricular pacing can produce systolic heart failure haemodynamically  
and neurohumorally similar to heart failure in humans [19].  These animal models of heart 
failure secondary to rapid pacing were initially developed to produce a reproducible source 
of animals with CMO [20].   
 
Haemodynamics 
In animal models, cardiac output and systemic pressures are reduced after 24 hours of rapid 
pacing [21].  Elevated filling and pulmonary artery pressures with an increase in systemic 
vascular resistance are observed after 1 week of rapid pacing.  With continued pacing, 
cardiac output and LVEF worsen over a period of 3 to 5 weeks [16].  Within 48 hours of 
termination of pacing, cardiac output increases and LV function starts recovering with 
normalisation after 1 to 2 weeks [22].  Diastolic dysfunction may persist after 4 weeks due to 
a persistence of structural changes [23].  In swine, rapid LA pacing at 240bpm results in 
heart failure, 18 to 23 days after pacing [24].  In dogs, rapid RV pacing at 250bpm for 3 to 4 
weeks results in heart failure [25]. 
 
Structural changes 
In animal models, rapid pacing results in dilatation of all 4 cardiac chambers [26].  LV 
dilatation is more marked for LVIDs than for LVIDd dimensions [27].  Hypertrophy of the 
walls is not observed with little or no change in myocardial mass [28].  Structural changes 
may persist at 4 weeks post pacing and end-systolic and end-diastolic volumes may remain 
elevated at 12 weeks after termination of pacing.  Hypertrophy may develop in the 4 weeks 
after discontinuation of pacing with the accumulation of large collagen fibre bundles [24]. 
 
Histological changes 
Histological changes occur in the myocyte and in the extracellular matrix.  Typically, there is 
a loss and elongation of myocytes [29, 30].  Disruption of the extracellular matrix results in 
misalignment of the myofibril and reduction in myocyte attachment to the basement 
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membrane.  There is an increase in B-actin, gamma-actin, alpha-tubulin and matrix 
metalloproteinases.  There is a decreased attachment to laminin, fibronectin, type IV 
collagen, with disruption of the sarcolemmal interfaces [31].  TGF-B-activin-A SMAD 
pathway may be involved.  In human studies, examination of endomyocardial biopsies with 
light microscopy displays non-specific findings. 
 
Neurohumoral changes 
Neurohumoral activation with increase in ANP, epinephrine, norepinephrine, renin and 
aldosterone levels is seen [32].  There is a diminished cardiac sympathetic responsiveness 
to beta-adrenergic stimulation (decrease in B1 receptor density, post-receptor abnormalities 
of adenyl cyclase and calcium handling) [33]. 
 
Electrical remodelling 
Rapid pacing produces alteration in ionic currents – so called electrical remodelling.  This is 
characterised by prolongation of the ventricular action potential duration (APD), effective 
refractory period (ERP) and QT interval [34].  Mechanisms that result in electrical 
remodelling are poorly understood.  Altered activation sequence even at physiological heart 
rates can induce electrical remodelling, APD prolongation and ionic current alterations over a 
short period.  There is usually a downregulation of Ito, IKs, Ik1 currents in ventricular myocytes 
[35].  
 
Mechanisms 
Myocardial energy depletion  
Animal studies have shown a depletion in high energy stores (decrease in creatine, 
phosphocreatine and ATP), diminished activity of the Na/K ATPase pump and 
mitochrondrial injury [36, 37]. 
Myocardial ischaemia 
There is impaired myocardial blood flow and elevated coronary vascular resistance with 
impaired coronary flow reserve [38].  Ischaemia may be a secondary mechanism in the 
development of TIC. 
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Abnormal Calcium cycling 
Abnormal cardiac Ca cycling may decrease Ca availability to myocytes with a reduction 
in cardiac contractility [37, 39]. 
Oxidative stress 
Oxidative stress is increased in experimental tachycardia-induced heart failure models.  
Probucol, an antioxidant, decreased LV dysfunction and remodelling in a canine model 
of TIC [40].    
 
Predictors of development of TIC in animals 
In the canine tachycardia experimental model, the response to tachycardia is highly variable. 
Pacing at a slower rate or for a shorter duration can produce lesser degrees of LV 
dysfunction [41].  Despite the same pacing rate, some animals developed heart failure 
symptoms and LV dysfunction after only a short duration of pacing, whereas other animals 
remain asymptomatic after many weeks of rapid atrial pacing [35].  Ventricular arrhythmias 
cause a more profound LV dysfunction than supraventricular arrhythmias in dogs [42].  
Predictors of TIC in animals remain undefined. 
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Predictors of development of TIC 
 
Similar to animals, not all patients with a chronic tachycardia will develop TIC.  The complex 
interaction of multiple tachycardia-related factors (including the rate, duration, type of 
tachycardia) and substrate-related factors (age, genetic factors, underlying structural heart 
disease) determine the development of TIC (Figure 1). 
 
Figure 1 
 
Tachycardia-related factors 
(Rate, duration, type of tachycardia) 
↓ 
Tachycardia ---------------------------------------------------------------------------------------------->TIC   
↑ 
Substrate-related factors 
(Age, genetic factors, underlying heart disease) 
 
Tachycardia-related factors 
 
Tachycardia rate  
The tachycardia rate needed to cause TIC is unclear.  No human studies have prospectively 
correlated heart rate with the development of TIC.  A few studies have determined that any 
prolonged ventricular rate >100bpm can potentially cause TIC [15, 43, 44].  However, 
another study of TIC secondary to AF showed that only 50% of patients had a resting ECG 
with a heart rate  >100bpm suggesting that an irregular rhythm without a resting tachycardia 
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can also potentially cause TIC [3].  Therefore, tachycardia rate is not the only predictor in the 
pathogenesis of TIC.   
In animal studies, ventricular pacing at faster rates leads to quicker deterioration in LV 
function than ventricular pacing at slower rates.  However, in clinical practice, patients with 
faster ventricular rates usually present earlier with troublesome symptoms and are treated 
before TIC can develop.  This paradox was evident in a recent study of TIC secondary to AT 
that concluded that slower tachycardia rates are generally better tolerated resulting in 
patients presenting later, allowing TIC to develop [12].  
In our study, 24-hour Holter monitoring was available for analysis in 9 patients (27%) before 
pure TIC was diagnosed.  All 9 patients who developed TIC had an incessant or continuous 
tachycardia with mean ventricular rates >97bpm and mean maximum ventricular rates of 
174 (range: 145-231) bpm.  In patients without Holter monitoring, mean resting ventricular 
rates in the pure TIC and impure TIC groups were 129+/-35 (range: 82-240) bpm and 138+/-
33 (range: 95-204) bpm respectively.  Our study found, similar to the findings of Packer et al 
[45], that a faster ventricular rate at presentation did not correlate significantly with a greater 
severity of LV dysfunction at presentation (Spearman r=-0.2295, P=0.21).    
There are inherent limitations in measuring mean tachycardia rates that lead to TIC.  Firstly, 
a  tachycardia may be paroxysmal and secondly, there may be wide day to day fluctuations 
in heart rate.  A resting pulse rate or a resting ECG is a snapshot in time and is a poor 
measure of mean heart rate.  Patients with apparently well-controlled resting heart rates may 
have a rapid ventricular response on activity.  A 24-hour Holter monitor which records 
ventricular rates during rest and exercise is a better monitor of mean heart rate but will not 
account for day-to-day differences in heart rate.  Most studies have reported tachycardia 
rates based on isolated resting ECGs without 24-hour Holter monitoring.  In our study, we 
increased the accuracy of mean heart rate by analysing all ECGs before presentation and all 
available 24-hour Holter recordings. 
 
Tachycardia duration 
The duration of tachycardia needed to cause TIC is unclear.  It is difficult to analyse the role 
of tachycardia duration independent of tachycardia rate and type.  In animal studies, rapid 
atrial or ventricular pacing at very fast rates results in heart failure within 3 to 4 weeks.  
However, in human studies, it is often the slower tachycardia that can be tolerated for a 
longer duration allowing TIC to develop insidiously [46].  A few studies have documented 
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that tachycardias had been present for many years before the index presentation of heart 
failure [3, 9].  All these studies have highlighted the limitations of determining tachycardia 
duration based on symptoms alone.  It has been stated that chronic or paroxysmal 
tachycardia occurring more than 10-15% of the day may result in LV dysfunction [5], but little 
evidence exists to support this statement.  Studies have shown that incessant or continuous 
tachycardias are more likely to cause TIC. 
No good measure exists to determine tachycardia duration.  In our study, we used duration 
of palpitations as a marker of tachycardia duration.  The median duration of palpitations was 
7 (1.3-51.0) and 3 (0.6-4.5) months in the pure and impure TIC groups respectively.  In our 
study, the median duration of tachycardia was shorter than has been published previously 
[3, 9, 12].  When comparing the pure and impure TIC group, we found no significant 
difference in the duration of palpitations, but dyspnoea duration was significantly shorter in 
the impure TIC group, suggesting that progression to heart failure occurs over a few months 
in patients with underlying structural heart disease with a tachycardia.  
Patients may not complain of palpitations in the presence of a tachycardia.  Six out of 33 
patients (18%) in the pure TIC group did not complain of any palpitations or were unable to 
define a duration of palpitations.  In these patients and in patients with paroxysmal 
tachycardias, the duration of the tachycardia based on symptoms is difficult to determine. 
Eleven out of 33 patients (33%) in our study had paroxysmal tachycardias. 
In our study, a longer tachycardia duration did not correlate significantly with a greater 
severity of LV dysfunction at pre entation (Spearman r=0.389384).  
 
Tachycardia type 
Any supraventricular or ventricular tachycardia can potentially cause TIC.  The causes of 
TIC are listed in Table 10.  In addition, frequent premature ventricular ectopy and persistent 
rapid atrial or ventricular pacing have been implicated.  In our study we were unable to 
determine the varying effects of different rhythms on the rate of development of TIC due to 
the small number of causative tachycardias in some groups. 
The type of tachycardia can influence the development of TIC.  TIC seems to develop most 
frequently in patients with AF, PJRT and ventricular ectopy followed by AFL, AT and 
AVNRT/AVRT.  
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AF is the most common cause of TIC.  In 2 studies, TIC developed in 11/29 (38%) patients 
with drug-refractory AF with/without heart disease and 9/30 (30%) patients with drug-
refractory lone-AF [5, 47].  In a large cohort of 63 patients with LV dysfunction referred for 
AVNA for drug-refractory AF, TIC developed in 16/63 (25%) patients [18].  In a recent cohort 
of 366 consecutive patients with AF referred for PVI, 67 (18%) patients had a decreased 
LVEF <50%.  Forty-one (11%) patients developed TIC with an increase in LVEF post 
ablation >5% [3].  In another study of 19 consecutive patients with drug-refractory AF 
referred for AV node modification, 12 (63%) had decreased LV function [48].  These studies 
suggest that TIC is prevalent in a population with drug-refractory AF.  The irregular 
ventricular rhythm of AF may adversely affect LV systolic performance independent of heart 
rate.  Hsu et al demonstrated that even patients with apparent heart rate control during AF 
on a 48-hour Holter monitor and depressed LV function had improvement in LV function 
following successful AF ablation [49].  Gentlesk et al further noted that only 50% of TIC 
patients who showed LV improvement had ECG documentation of heart rates >100bpm [3]. 
It has been noted that LV function may improve in patients with chronic AF and mean resting 
heart rates <100bpm and AVNA (Helguera, ACC abstract 1994).  Therefore, both rate and 
regularization of ventricular contraction seem to be important in reversing TIC and AF.   
A study of TIC secondary to focal AT showed that TIC developed in 10% of patients with AT 
[12].  TIC patients who were more likely to be young, male, have incessant tachycardia and 
longer AT cycle lengths and slower ventricular rates during the tachycardia than those with 
AT without TIC.  In 2 studies of persistent AFL, TIC developed in 11-14% of patients who 
were referred for an AFL ablation [2, 15].  In another study of 17 patients with incessant 
AVRT caused by a concealed AP referred for ablation, TIC developed in 7 (41%) patients 
[50].  These patients were younger and had the tachycardia earlier in life.  In a study of 300 
patients with AVNRT or AVRT referred for ablation, TIC developed in 14 (<1%) patients [51].  
In animal models, ventricular arrhythmias cause more profound depression in LV function 
than do supraventricular arrhythmias [42, 52].  Frequent premature ventricular ectopy can 
cause TIC.  In a study of 60 consecutive patients with frequent PVC’s (>10/hour, 11% of all 
QRS complexes), LV dysfunction was present in 22 (37%) and in 18 (30%) patients, LV 
function normalised after successful PVC ablation [53].  Another study by Takemoto et al 
suggested that RVOT VPC’s >20% (20000 VPC’s/day) of the day decreased LVEF and 
increased LV dimensions [54].  In a study by Yarlagadda et al,  patients who developed TIC 
were older than those who did not develop TIC despite having significantly more ventricular 
ectopy.  Patients who developed TIC occurred even in patients with 5500 VPC’s/day [55].  
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In a study of 174 consecutive patients referred for ablation of frequent idiopathic PVC’s, a 
PVC burden (percentage of total beats that were PVC’s) of >24% was strongly associated 
with a PVC-induced cardiomyopathy with a sensitivity and specificity of 80%.  No patients 
developed a cardiomyopathy in this study with a PVC burden < 10%.  The PVC burden 
(and not site of origin of ectopy) was the only independent predictor of development of a 
cardiomyopathy [56]. 
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Substrate factors 
 
Genetic factors 
An intriguing aspect of the development of TIC is the role of underlying genetic susceptibility.  
In alcoholic CMO, there seems to be an underlying genetic basis for the observation that 
only some patients will develop an alcoholic CMO if exposed to chronic alcohol use.  A DD 
ACE genotype increased the risk of developing an alcoholic CMO by a factor of 14 [57].  
This observation has led some to postulate that ACE gene I/D polymorphisms may account 
for the CMO secondary to a tachycardia [58].  The DD ACE genotype was significantly more 
common in patients with TIC than controls and the ID ACE genotype. 
 
Underlying structural heart disease 
It is unknown whether patients who have underlying structural heart disease are at more or 
less risk of developing TIC.  It has been observed that patients with underlying structural 
heart disease may develop TIC more quickly [5].  Our study supports this observation.  We 
noted that patients with impure TIC reported a shorter duration of dyspnoea and were more 
symptomatic compared to patients with pure TIC.  This observation suggests that patients 
with underlying structural heart disease may develop LV dysfunction more quickly and 
present earlier with symptoms and signs of heart failure.  The observation that a recurrence 
of a tachycardia in a TIC patient who has recovered LV function leads to a precipitous 
decline in LV function supports the above observation [9]. 
 
Gender 
Many, but not all, studies have shown a strikingly male predominance in the development of 
TIC [2, 3, 9, 11, 14, 15, 44, 53].  Whether this association is causative or simply reflects 
referral bias is unclear. 
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Rate of deterioration of left ventricular function  
 
The complex interplay of all the above variables results in marked variability in the rate of 
development of TIC and the rate deterioration of LV function. 
For example, a patient with no pre-existing heart disease may tolerate a slow 
supraventricular tachycardia for years and may present years after the onset of the 
tachycardia as compared to a patient with underlying structural heart disease who may 
deteriorate more quickly and present within months with symptoms.  
Many studies have reported a slow insidious rate of development of TIC, typically over 
months to years from the onset of tachycardia or symptoms of palpitations.  However, the 
same studies highlight the limitations of determining the duration of the tachycardia based on 
symptoms alone.  Moreover, baseline echocardiograms confirming preserved LV function 
predating the tachycardia are often unavailable in individual patients making the precise rate 
of deterioration of LV function difficult to determine.  
In our study, we observed that although a tachycardia had been documented for many 
months or years, when LV dysfunction ensues, rapid deterioration in LV function can occur 
over a period of a few months.  We noted in 5 patients with pure TIC, who had preserved LV 
function documented prior to the development of TIC that, although the palpitations had 
been present for a mean of 50 months, LV function deteriorated rapidly over a mean period 
of 6 months when the tachycardia was poorly controlled.  In 1 patient with impure TIC who 
had a recurrence of the tachycardia, the LV function deteriorated over a period of 1 month.  
This highlights the importance of prompt effective rate or rhythm control of a tachycardia 
before LV dysfunction ensues.  
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Diagnosis 
 
TIC is a diagnosis of exclusion.  A definite diagnosis of TIC requires measurement of LV 
function prior to the onset of uncontrolled tachycardia and documentation of worsening LV 
function in the setting of the tachycardia with improvement in LV function after control of the 
ventricular rate.  However, most patients will not have had LV function measured prior to the 
start of the tachycardia and therefore the diagnosis can only be made retrospectively after 
LV function improves with control of the tachycardia.  It is important to remember that 
frequent ventricular ectopy has also been implicated.  Therefore, TIC should be suspected in 
any patient with clinical or investigational evidence of impaired LV function, with or without 
underlying pre-existing structural heart disease, in the setting of any supraventricular or 
ventricular tachycardia and/or frequent ventricular ectopy.    
 
Clinical features  
The clinical presentation of TIC is highly variable.  Presentations range from asymptomatic 
LV dysfunction to severe advanced heart failure with a wide spectrum of presentations in-
between.  Many patients will not complain of palpitations and most will present with heart 
failure symptoms.  Recognising a tachycardia or ventricular ectopy in the setting of LV 
dysfunction is the clue to diagnosis.  It is important to remember that TIC can develop in 
patients with or without pre-existing structural heart disease, congenital or acquired.  TIC can 
present at any age, including the foetus to the elderly. 
The most common foetal tachyarrhythmias are atrioventricular re-entry tachycardia 
caused by an accessory pathway (90% of foetal supraventricular tachycardia) and atrial 
flutter.  Ventricular tachycardia and atrial fibrillation are rarely detected in utero.  
Persistent foetal tachycardias should be promptly treated with anti-arrhythmic drugs given 
transplacentally or via direct foetal transfer to treat hydrops foetalis. In one study of foetal 
tachycardias, non-hydropic foetuses had a very good prognosis (mortality rate 4%) with 
transplacental treatment with anti-arrhythmic drugs.  Although most arrhythmias 
associated with hydrops foetalis could be controlled by transplacental treatment, the 
mortality rate was much higher at 27% [59]. 
In our study, patients with pure TIC generally had a better effort tolerance (NYHA class), 
complained of more palpitations and had fewer clinical signs of heart failure at presentation 
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compared to patients with DCMO.  However, a wide range of clinical presentations were 
seen.  The range included patients who had a normal effort tolerance and no signs of heart 
failure to patients with severe advanced heart failure who were considered for cardiac 
transplantation.  In these cases, it was difficult to determine whether the tachycardia was 
causal or secondary to the CMO on clinical grounds.  Documentation of AF that predates LV 
dysfunction by months/years may be a useful pointer to a diagnosis of TIC as AF tends to 
develop late in the course of DCMO [60].  In our control group, only 6 out of the 25 (25%) 
patents with DCMO were in AF.  Patients with impure TIC had generally a shorter duration 
and more severe symptoms at presentation. 
 
Electrocardiographic features  
To our knowledge, the electrocardiographic characteristics of TIC have not been previously 
reported.  In our study, we found that TIC patients had shorter QRS durations and were less 
likely to have Q-waves, LVH and repolarization abnormalities compared to patients with 
DCMO.   
A previous study showed that certain electrocardiographic features may be useful for 
differentiating between DCMO and ischaemic CMO [61].  DCMO was characterised by 
higher RV6 voltages and higher RV6/Rmax (leads I, II or III) ratios.  The authors stated that 
RV6 voltage is determined by the distance from the LV to the RV6 chest lead and is a marker 
of LV dilatation.  Limb voltages in leads I, II, III are not affected by the distance of the LV to 
the chest wall and are markers of voltage producing cardiac mass.  In patients with DCMO, 
replacement fibrosis or infiltrates reduce R wave voltages in these limb leads.  When we 
compared TIC patients with DCMO patients, there were no significant differences in RV6 
voltages and RV6/Rmax ratios between the 2 groups.  By inference RV6 voltages and 
RV6/Rmax ratios may be useful parameters to distinguish between DCMO or TIC from 
ischaemic CMO but not useful to distinguish between DCMO and TIC. 
 
Echocardiographic features 
A previous study by Jeong et al showed that TIC patients tended to have smaller LV mass 
indices, volume dimensions and LV dimensions compared to patients with DCMO [11].  They 
suggested that a LVIDd <=6.1cm at presentation predicted TIC with a sensitivity of 100% 
and a specificity of 71%.  Our study confirmed that pure TIC patients had significantly 
smaller LVIDd, LVIDs and LA dimensions when compared to DCMO patients at 
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presentation.  However, in contrast to their study, we could not confirm a LVIDd dimension 
that predicted TIC with a high degree of sensitivity and specificity.  In our study, secondary 
MR was common.  MR was often mild to moderate in severity and tended to improve after 
control of the tachycardia.  An animal sheep study of TIC showed that MR resulted from 
decreased leaflet coaptation secondary to annular dilatation in the septal-lateral direction 
[62].  Subvalvular leaflet tethering does not seem to play a major role in the pathogenesis of 
MR presumably because TIC patients may have preserved LV size and volumes. 
 
MRI features 
There are few published reports of TIC who have undergone MRI.  MRI is known to be a 
useful tool to differentiate between DCMO, HCM, ARVC and non-compaction CMO.  The 
MRI characteristics of TIC needs further study.  We report the MRI findings of 1 patient with 
TIC secondary to AFL who underwent MRI at presentation.  She had LV chamber 
enlargement with elevated end-systolic and diastolic volumes, LVEF 39%, and 3 dyskinetic 
segments.  She had no features of fibrosis on delayed contrast enhancement.  After AFL 
ablation, her LV function improved over 6 months.  An interesting aspect for further research 
would be to investigate the prognostic value of MRI in predicting LV function improvement.  
Hypothetically, longstanding TIC may have higher degrees of delayed contrast enhancement 
reflecting extensive fibrosis of the ventricles on MRI which may predict lesser degrees of LV 
improvement after control of the tachycardia.  
 
Dobutamine stress echocardiography 
A study by Paelinck at al suggested that low-dose dobutamine stress echocardiography 
(DSE) can be used to predict improvement in LVEF in patients with CMO and AF after 
conversion to sinus rhythm [63].  Patients who showed an increase in LVEF with DSE were 
more likely to improve LVEF after correction to sinus rhythm and be diagnosed with TIC.   
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Management 
 
Management of TIC is essentially twofold.  Firstly, aggressive control or stopping of the 
tachycardia is essential.  Secondly, standard heart failure drugs including Beta-Blockers (if 
tolerated), ACE-inhibitors or angiotensin-receptor blockers should be prescribed.  The best 
means to achieve heart rate control vary depending on the type of arrhythmia.  A recent 
guideline on the management of TIC has been published [64].  All the recommendations are 
based on expert opinion or small case studies.   
Radiofrequency ablation is considered first-line therapy in most arrhythmias resulting in TIC. 
In patients with AF, either a rate or rhythm control strategy can be applied.  Medical therapy 
to slow ventricular rate or prevent recurrences, prior to radiofrequency ablation, of if 
radiofrequency is unavailable, should be tried but may not be effective. 
 
Rate or rhythm control for AF? 
What remains unclear is whether a rate or rhythm control strategy is better in AF-induced 
TIC.  The results of the AF-CHF trial conducted in patients with AF and LV dysfunction 
showed that there was essentially no difference between a rate and rhythm control strategy 
[65].  However, these results may not be directly applicable to TIC.  Another study by Hsu et 
al favoured a rhythm control strategy showing that LV function improved even in patients 
with apparent well-controlled heart rates [49].  Recently, pulmonary vein isolation was shown 
to be effective in patients with AF and depressed LVEF in reversal of TIC [3]. 
 
Rate control 
Rate control of AF can be achieved by AV nodal blockers (Beta-Blockers, Calcium-channel 
blockers, digoxin), anti-arrhythmic therapy (amiodarone, sotalol) or if medication is 
ineffective, AVNA and PPM implantation.  However, what constitutes “successful” rate 
control is unclear and is not evidence-based.  In the AFFIRM trial, rate control was defined 
as a resting heart rate <=80bpm and either a maximum of <=110bpm during a 6 minute walk 
test or a mean <100bpm on 24-hour Holter monitoring, with the rate not exceeding 110% of 
maximum predicted age-adjusted exercise rate [66].  The RACE trial used a simpler 
definition of <=100bpm [67], while HOTCAFE required a resting heart rate 70 to 90bpm and 
<=140bpm during moderate exercise [68].   
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In our study, we noted in 4 patients with AF that although pharmacological rate control was 
suboptimal (according to the AFFIRM trial criteria), LV function improved in all patients at a 
slower rate over a year (Graph 2, Group B and Table 7).  In contrast, we noticed that in 
patients who had AVNA/PPM implanted for failed pharmacological rate control, the LV 
function generally had maximal improvement by 3 to 6 months.  These findings suggest that 
although strict rate control is required for optimal LV recovery, lenient rate control may still 
result in improvement.  In the RACE II trial, a randomized trial of optimal heart rate control 
versus lenient heart rate control in patients with permanent AF found no difference between 
the 2 strategies [69].  However, TIC patients were underrepresented in this trial.  It remains 
unclear whether TIC patients may benefit from stricter heart rate control and, therefore, 
clinicians should still aim for rate control according to the above AFFIRM criteria.   
 
Rhythm control 
Rhythm control can be achieved by pharmacological or electrical cardioversion, 
antiarrhythmic drugs or catheter ablation of AF.  AF burden is defined as the total percent of 
time a patient is in AF which is determined by the number and duration of AF episodes.  A 
major reduction in the frequency and duration of symptomatic AF episodes is an acceptable 
endpoint [70]. 
 
Anti-failure treatment 
There is currently no recommendation as to how long to continue with anti-failure treatment.  
Studies have shown that although the LVEF may normalise post treatment, adverse LV 
remodelling persists as suggested by elevated LVIDd dimensions compared to controls [10].  
This observation suggests without firm evidence that RAAS-inhibitors and Beta-Blockers 
should probably be continued in TIC patients with persistent LV dysfunction and/or LV 
dilatation. 
 
Follow-up 
Patients with TIC require careful follow-up.  Recovery may be unpredictable and close 
observation is required in these patients.  Recurrence of the tachycardia can result in a 
precipitous decline in LV function and one report has suggested that the risks of sudden 
cardiac death is increased [9].   
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Recovery of left ventricular function 
 
In animal studies, impaired LV function improves within 48 hours of cessation of pacing and 
returns to normal by 1 to 2 weeks.  In human studies, however, LV recovery takes months to 
years and is usually unpredictable.  Factors such as the severity and duration of LV 
dysfunction, presence of pre-existing structural heart disease and extent of control of the 
tachycardia determine the degree and rate of LV recovery. 
 
Degree of recovery 
The degree of recovery of LV function after control of the causative tachycardia can range 
from complete, partial to totally absent.  It is likely that TIC involves a spectrum extending 
from a “stunned” myocardium with complete reversibility to a “burnt-out” phase which is 
irreversible.   
A study by Luchsinger et al showed that patients with AFL with LV dysfunction who did not 
improve post ablation had a worse LVEF and NYHA functional class before ablation 
compared to patients who had improvement of LV function [15].  This study reported that 
severe LV dysfunction secondary to AFL was a predictor of partial or no improvement 
presumably because severe LV dysfunction may be secondary to irreversible myocardial 
damage.  There was no difference in age or AFL duration between those who improved and 
those who did not.  In contrast, another study of patients with AFL found that a rapid 
ventricular rate during AFL was the only independent predictor of reversibility of the CMO [2].  
In this study, 75% of patients with a heart rate >100bpm improved compared to only 25% of 
patients with a ventricular response less than 100bpm.  The observation that a higher 
percentage of non-responders occurred in studies that included patients with underlying 
structural heart disease [2, 3, 15] compared to studies that have excluded underlying heart 
disease [12, 51] suggests that pre-existing structural heart disease may be a predictor of a 
poor response.   
In our study, severe LV dysfunction at presentation was not a predictor of partial 
improvement of LV function after control of the tachycardia.  In 8 out of 12 (75%) patients 
with severe LV dysfunction (LVEF <30%), LVEF improved to >=50%.  However, we found 
that patients who had severe symptomatic (NYHA III, IV) heart failure at presentation tended 
to have lesser degrees of LV improvement (p=0.041).  There was no correlation between the 
LVIDd at presentation and the degree of recovery of LV function (r=-0.1408, p=0.554).    
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Theoretically, patients with a longer duration of LV dysfunction and/or duration of the 
tachycardia may have partial improvement because of long-standing irreversible damage. 
We were unable to investigate whether long-standing LV dysfunction predicted poorer 
recovery as it was difficult to determine how long patients had tachycardia-induced LV 
dysfunction.  We did note, however, in 3 patients (patient  8, patient 29, patient 32) who had 
a history of 10 to 20 years of AF, despite initial pharmacological rate control and later 
AVNA/PPM implantations, that recovery of LV function was incomplete at late follow-up.   
In order to identify predictors of LV improvement, we compared patients who had partial LV 
improvement (LVEF <50%) with patients who had recovered LV function (LVEF >=50%) at 
last follow-up.  Patients who had partial improvement had significantly wider QRS durations 
at presentation which presumably reflects widespread permanent underlying structural 
damage.   
 
Rate of recovery 
Some studies have indicated that LV function improvement is expected within a few days to 
weeks after rate or rhythm control of the underlying tachycardia, followed by a slower rate of 
improvement that reaches its maximum after 3 to 6 months [5, 9, 71].  Some studies have 
also noted that patients with severe tachycardia-mediated injury may have greater 
improvement at late follow-up compared to early follow-up [45, 51].  
In our study, we observed that maximal recovery of LV function was usually achieved by 3 to 
6 months, with little improvement noted after 6 months.  In patients who had severe LV 
dysfunction or who had lenient rate control, improvement occurred over a 6 to 12 months 
period.  These findings suggest that prompt rate or rhythm control of the tachycardia is 
necessary for optimal LV extent and rate of recovery.  However, lenient rate control may 
lead to improvement but at a slower rate.   
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Left ventricular remodelling 
 
In animal studies, although LV systolic function recovers rapidly after cessation of pacing, 
diastolic dysfunction, fibrosis and cellular Ca alterations persist and LV hypertrophy develops 
during the recovery phase.  Persistent structural abnormalities may persist in patients who 
have severe chamber dilatation or have a prolonged duration of the tachycardia [72].  This is 
supported by histological studies that have documented myocardial fibrosis even in patients 
who have recovered LV function [73].  LV hypertrophy after recovery is not recognised in 
human studies.  Echocardiographic evaluation of diastolic function after normalisation of LV 
function has not been reported. 
One study showed that although the LVEF improved significantly with control of the 
tachycardia, LV dimensions and volumes remain significantly elevated when compared to 
control patients late after control of the tachycardia [10].  In our study, when we compared 
TIC patients who had complete improvement, with age and LVEF matched control subjects 
with normal echocardiograms, TIC patients had a trend towards greater LVIDd dimensions, 
indicating persistence of adverse LV remodelling at follow-up.  Similar to previous studies, 
we noted a significant decrease in the LVIDd and LVIDs dimensions post treatment [3, 51]. 
In other studies, the increase in LVEF was mainly due to a decline in end-systolic dimension, 
whereas the end-diastolic diameter was not significantly changed [44, 50].  In our study, LA 
dimensions remain significantly elevated at follow-up, suggesting persistence of adverse 
atrial remodelling and providing a potential substrate for atrial arrhythmias. 
In our study, TIC patients with dilated ventricles at presentation were more likely to have 
residual LV dilatation at follow-up (r=0.68, p=0.002, Graph 5).  This observation stresses the 
importance of repeated echocardiographic measurements at follow-up and the prescription 
of Beta-blockers and RAAS inhibitors to prevent adverse ventricular remodelling in all TIC 
patients if tolerated.  In particular, patients with dilated ventricles at presentation should be 
followed up carefully as they are more likely to have dilated ventricles at late follow-up.  
There have been no studies investigating the long-term role of Beta-blockade and RAAS-
inhibitors in patients with TIC and after control of the tachycardia.  Until further data becomes 
available, it would be reasonable to continue Beta-blockade and RAAS-inhibitors indefinitely 
in all patients who have LV dysfunction and/or LV dilatation at follow-up. 
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Recurrence of tachycardia 
 
Nerheim et al reported 5 patients with recurrent tachycardia which caused a rapid decline in 
LV function and development of heart failure in all patients [9].  These patients had an abrupt 
fall in LVEF within 6 months and reversed again within a similar period.  Since that initial 
observation, another study reported 2 patients with recurrence of the tachycardia and TIC 
[14].  Notably, these 2 patients had a very short period of symptoms from the 
tachyarrhythmia (12 days, 1 day) to presentation.  Our study is the third report with recurrent 
tachycardias occurring in 3 patients.   
Patient 1 developed an impure TIC secondary to an orthodromic AVRT with a previous 
inferior myocardial infarction.  The presenting LVEF was 21%.  He was started on 
metoprolol, enalapril and diuretics.  At a 3 week follow-up visit, his symptoms had markedly 
improved with a repeat echocardiogram showing a LVEF of 51%, confirming a diagnosis of 
TIC.  Unfortunately, he defaulted medical therapy and represented with recurrence of the 
AVRT 4 months later.  An echocardiogram confirmed that his LV function had deteriorated to 
a LVEF of 35%.  His accessory pathway was successfully ablated.  At 2 year follow-up, he 
reported no recurrences of palpitations or AVRT.  His last follow-up echocardiogram showed 
a LVEF of 47%.  This case highlights the observation that recurrence of tachycardia may 
lead to a rapid decline in LV function.  
 Patient 4 developed a pure TIC secondary to 2 different ATs with a presenting LVEF of 
16%.  Only one of the ATs could be ablated.  Nevertheless, the LVEF improved to 61% 1 
year after ablation.  The patient was continued on antiarrhythmic therapy.  Eighteen months 
later, the first AT recurred with a deterioration in LVEF to 50% with mean heart rates on 
Holter of 119bpm.  Pharmacological rhythm control was preferred.  At last follow-up the 
LVEF had improved to 53%.  
Patient 23 developed a pure TIC secondary to rapid AFL with a presenting LVEF of 40%.  
While awaiting ablation of the AFL, the LVEF improved to 50% with pharmacological rate 
control.  AFL ablation was unsuccessful.  His AFL persisted and pharmacological AFL rate 
control  (mean heart rates 97bpm) was noted to be suboptimal.  This led to a slow 
progressive decline in LV function over 3 years (LVEF 32%).  Successful AFL ablation led to 
improvement in LV function to LVEF of 53% 5 months after ablation.  This last case 
demonstrates that LV function may gradually deteriorate over time, if rate control is 
suboptimal.   
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Prognosis and long-term follow-up 
 
The long-term prognosis of TIC has not been established.  Nerheim et al documented 3 TIC 
patients who had recovered LV function and had sudden cardiac death [9].  A study by 
Fujino [13], showed that cardiac death and recurrent hospitalisations were significantly less 
in the TIC group than a DCMO group. 
In our study, 33 pure TIC patients were followed up for a mean period of 6.8 (range: 1 to 
19) years.  Twenty patients were confirmed alive at the time of writing this paper. There 
were 3 confirmed deaths.  The nature of the 1 death was due to a cholangiocarcinoma.  
The causes of death in the other 2 patients could not be determined from clinical records. 
Ten out of 33 patients could not be contacted. Of the 10 patients, 4 were discharged in a 
stable condition from the cardiac clinic.  Three patients were discharged in a stable 
condition to other hospitals around South Africa. Three patients did not return for routine 
follow-up visits.  We cannot exclude sudden cardiac deaths in patients who were not 
confirmed to be alive.  In contrast, 14 out of 25 patients were alive in the DCMO control 
group.  As a large number of TIC patients were lost to follow-up, we could not make a 
meaningful comparison with DCMO patients regarding long-term prognosis and outcome. 
To our knowledge, there have been no reports of secondary ventricular arrhythmias in 
patients with resolved TIC.   
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LIMITATIONS 
 
This is a retrospective study with a small number of TIC patients.  The patients represent 
a select group of non-consecutive patients referred to a regional referral hospital.  It is 
likely that a sizeable number of patients with TIC were not included in this study.  The true 
prevalence of TIC in patients with tachycardia can only be answered by a prospective 
study or CMO registry.  
Although care was taken to examine all ECGs prior to presentation to calculate average 
heart rate, this may not be a true reflection of average heart rate during a 24 hour period.  
An accurate duration of the tachycardia before presentation was difficult to determine.  
Patients cannot always recall the exact duration of palpitations and patients could have a 
tachycardia for a variable length of time before an ECG is performed.  
Not all patients with pure TIC had coronary angiography to exclude coronary artery 
disease, although no coronary intervention was performed between presentation and 
when LV function had recovered to account for improvement in LV function.   
Not all patients at presentation had echocardiography performed in sinus rhythm. The 
calculation of LV systolic function in the presence of a shortened diastolic filling time may 
result in an underestimate of LVEF.  In this study we were unable to control for the effects 
of differences in heart rate or rhythm in the assessment of LV function at initial 
presentation and after control of the tachycardia.  Unfortunately, heart rate and rhythm at 
the time of initial LV assessment at echocardiography were not routinely recorded on 
echocardiography or radionucleotide imaging reports at our institution.  However, 
echocardiographic reports at slower heart rates were preferentially recorded for LV 
function assessment for better accuracy of LV function.  When more than one 
echocardiogram was performed in short succession, an average of the LVEF and LV 
dimensions were calculated from serial echocardiograms to improve accuracy.  In some 
cases, echocardiography was not performed at our institution.   Echocardiography and 
interpretation of ECGs were often the interpretation of one cardiologist.   
The small control group of 25 DCMO patients was limited by the number of DCMO 
patients available in the CMO registry.  Treatment of tachycardia varied between 
cardiologists and was not administered uniformly.  The long-term prognosis of TIC could 
not be accurately determined because a large number of patients were lost to follow-up 
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who were not contactable.  There was no standard follow-up time.  Not all patients had 
repeat echocardiograms and echocardiograms were performed at variable time periods. 
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CONCLUSIONS 
 
This is one of the largest retrospective studies of TIC and the first large series from Africa. 
This study is the first to compare features of pure and impure TIC.  We found that impure 
TIC may develop more quickly than pure TIC as impure TIC patients have a shorter duration 
and more severe symptoms at presentation.  This observation suggests that underlying 
structural heart disease is a risk factor in the development of TIC.  This study reports the first 
description of ECG findings of TIC.  Patients with pure TIC have shorter QRS durations, less 
LVH, Q waves and repolarization abnormalities at presentation compared to DCMO patients.  
This is the second study to report that TIC patients have smaller LVIDd dimensions at 
presentation and have persistence of adverse LV remodelling as characterised by persistent 
enlargement of LVIDd  dimensions at late follow-up.  Patients who have larger LVIDd 
dimensions at presentation tended to have larger LVIDd dimensions at late follow-up, 
identifying a subgroup of patients where careful follow-up is required.  This study confirms 
that maximal improvement of LV function generally occurs by 3 to 6 months.  However, we 
noted slower improvement in LV function over 12 months in patients who had severe LV 
dysfunction and in patients with AF who had lenient heart rate control.  The only predictor of 
LV improvement was a shorter QRS duration at presentation.  We managed to identify 45 
patients with this condition at a large regi nal referral centre in Cape Town over a 15 year 
period, suggesting that this condition is frequently under-diagnosed and missed.   
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ADDENDUM 
 
TABLES 1-10 
 
GRAPHS 1-5 
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TABLE 2A: 
Patient demographics and clinical features of pure and impure TIC 
 
 
Patient demographics 
and clinical features 
 
Pure TIC group 
(n=33) 
 
Impure TIC group 
(n=12) 
 
P value  
 
Age (years) 
 
Sex (no. (%)) 
   Male 
   Female 
    
 
44 (30-62) 
 
 
25 (75.8%) 
8 (24.2%) 
 
39 (23-59) 
 
 
9 (75.0%) 
3 (25.0%) 
 
0.26 ¶ 
 
0.96 * 
 
NYHA (no. (%)) 
   NYHA I,II 
   NYHA III, IV 
   Unknown 
 
Dyspnoea duration 
(months) 
 
Palpitations duration 
(months) 
 
Signs of heart failure 
(no. (%)) 
   Yes 
   No 
   Unknown 
 
 
10 (30.3%) 
21 (63.6%) 
2 (6.1%) 
 
 
2 (0.6-7.5) 
 
 
7 (1.3-51.0) 
 
 
 
15 (45.5.%) 
18 (54.5%) 
0 
 
 
1 (8.3%) 
11 (91.7%) 
0 (0.0%) 
 
 
0.50 (0.2-2.0) 
 
 
3 (0.6-4.5) 
 
 
 
9 (75.0%) 
1 (8.3%) 
2 (16.7%) 
 
0.11 * 
 
 
 
 
0.04 ¶ 
 
 
0.45 ¶ 
 
 
0.003 * 
 
¶ Mann-Whitney Test 
* Chi-Square Test 
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TABLE 2B:  
Electrocardiographic features of pure and impure TIC 
 
 
ECG features 
 
Pure TIC group 
(n=33) 
 
Impure TIC group † 
(n=10)  
 
P value * 
 
Sinus Rhythm 
   Yes 
   No 
    
LA hypertrophy 
   Yes 
   No 
   Unable to assess 
 
Q waves 
   Yes 
   No 
 
LBBB 
   Yes  
   No 
 
RBBB 
   Yes 
   No 
 
LV hypertrophy 
   Yes  
   No 
 
Repolarization 
abnormalities 
   Yes 
 
 
6 (18.2%) 
27 (81.8%) 
 
 
3 (9.1%) 
6 (18.2%) 
24 (72.7%) 
 
 
2 (6.1%) 
31 (93.9%) 
 
 
2 (6.1%) 
31 (93.9%) 
 
 
1 (3.0%) 
32 (97.0%) 
 
 
4 (12.1%) 
29 (87.9%) 
 
 
 
18 (54.5%) 
 
 
3 (30.0%) 
7 (70.0%) 
 
 
3 (30.0%) 
0 (0.0%) 
7 (70.0%) 
 
 
1 (10.0%) 
9 (90.0%) 
 
 
0 (0.0%) 
10 (100.0%) 
 
 
0 (0.0%) 
10 (100.0%) 
 
 
7 (70.0%) 
3 (30.0%) 
 
 
 
7 (70.0%) 
 
0.21 
 
 
 
0.05 
 
 
 
 
0.67 
 
 
 
0.43 
 
 
 
0.58 
 
 
 
<0.001 
 
 
 
0.39 
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   No 
 
QRS width (ms) 
 
RV6 (mV) 
 
RV6/Rmax 
 
15 (45.5%) 
 
92 (71-152) 
 
         1.5+/-0.7 
 
1.8+/-0.7 
3 (30.0%) 
 
102 (72-117) 
 
1.6+/-0.3 
 
2.1+/-0.8 
 
 
0.20 ¶ 
 
0.04 ∫ 
 
0.78 ∫ 
 
 
† The ECGs of 2 patients with impure TIC were unavailable for analysis 
¶ Mann-Whitney Test 
* Chi-Square Test 
∫  T-test 
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TABLE 2C:  
Echocardiographic features of pure and impure TIC 
 
 
Echocardiographic  
features  
 
Pure TIC group 
(n=33) 
 
Impure TIC group 
(n=12) 
 
P value ∫  
 
LVEF (%) 
 
LVIDd (cm) 
 
LVIDs (cm) 
 
LA size (cm) 
 
32.4+/-9.5 
 
5.7+/-0.7 
 
4.8+/-0.8 
 
4.2+/-1.0 
 
29.2+/-1.0 
 
5.7+/-1.0 
 
4.8+/-0.8 
 
4.8+/-1.5 
 
0.80 
 
0.06 
 
0.76 
 
0.30 
 
 
∫  T-test 
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TABLE 3:  
Arrhythmic causes of pure and impure TIC 
 
 
Causative 
tachycardia 
 
Pure TIC group  
(n=33) 
n (%) 
 
Impure TIC group  
(n=12) 
n (%) 
 
 
Atrial fibrillation 
 
Typical atrial flutter 
 
Atrial tachycardia 
 
Atypical atrial flutter 
 
AVNRT 
 
AVRT 
 
Fascicular VT 
 
 
 
20 (60.6%) 
 
6 (18.2%) 
 
4 (12.1%) 
 
1 (3.0%) 
 
1 (3.0%) 
 
0 (0.0%) 
 
1 (3.0%) 
 
 
 
5 (41.7%) 
 
3 (25.0%) 
 
0 (0.0%) 
 
1 (8.3%) 
 
2 (16.7%) 
 
1 (8.3%) 
 
0 (0.0%) 
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TABLE 4: 
Comparison of clinical, electrocardiographic and echocardiographic features of pure 
TIC and DCMO matched for age, sex and LVEF   
 
 
Patient demographics 
and clinical features 
 
Pure TIC group 
(n=25) 
n (%) 
 
DCMO group  
(n=25) 
n (%) 
 
P value * 
Age 46 (16-67) 46 (21-65) 0.846 ¶ 
Sex       
   Male 
   Female 
 
 19 (76%)  
6 (24%) 
 
19 (76%) 
6 (24%) 
1.00 
NYHA   
   NYHA I, II 
   NYHA III, IV 
 
9 (36%) 
16 (64%) 
 
4 (16%) 
21 (84%) 
0.02 
Palpitations    
   Yes 
   No 
 
21 (84%) 
4 (16%) 
 
12 (48%) 
13 (52%) 
0.007 
Signs of heart failure   
  Yes 
  No 
 
12 (48%) 
13 (52%) 
 
21 (84%) 
4 (16%) 
0.007 
 
 
ECG features 
   
Sinus Rhythm  
  Yes 
  No 
 
5 (20%) 
20 (80%) 
 
19 (76%) 
6 (24%) 
<0.001 
LA enlargement 
  Yes 
  No 
  Unable to assess 
 
3 (12%)  
5 (20%) 
17 (68%) 
 
8 (32%) 
11 (44%) 
6 (24%) 
0.546 
Q waves 
   Yes 
   No 
 
1 (4%) 
24 (96%) 
 
10 (40%) 
15 (60%) 
0.002 
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LBBB 
  Yes 
  No 
 
2 (8%) 
23 (92%) 
 
6 (24%) 
19 (76%) 
0.123 
RBBB 
  Yes 
   No 
 
1 (4%) 
24 (96%) 
 
0 (0%) 
25 (100%) 
0.5 
LVH 
  Yes 
  No 
 
4 (16%) 
21 (84%) 
 
14 (56%) 
11 (44%) 
0.004 
Repolarization 
abnormalities  
  Yes 
  No 
 
 
16 (64%) 
9 (36%) 
 
 
22 (88%) 
3 (12%) 
0.048 
QRS width (ms) 88 (82-102) 100 (92-110) 0.024 ¶ 
RV6 (mm) 15.8+/-7.5 15.0+/-11.2 0.79 ∫ 
RV6/Rmax 1.84+/-0.8 1.69+/-1.2 0.63 ∫ 
 
 
Echocardiographic 
features 
   
LVEF (%) 30.8+/-9.5 27.8+/-10.2 0.29 ∫ 
LVIDd (cm) 5.7+/-0.7 6.6+/-0.6 <0.001 ∫ 
LVIDs (cm) 4.9+/-0.8 5.7+/-0.6 0.001 ∫ 
LA size (cm) 4.1+/-1.0 4.6+/-0.5 0.048 ∫ 
 
¶ Mann-Whitney Test 
* Chi-Square Test 
∫  T-test 
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TABLE 5:  
Patients showing rate of deterioration of left ventricular function  
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
(no.) 
 
Causative 
tachycardia 
 
Average 
ventricular 
rate during 
tachycardia 
(bpm) 
 
LVEF  
before TIC  
(%) 
 
TIC LVEF 
(%) 
 
Medication 
 
Time period 
of 
deterioration 
(months) 
Patient 3 AF 89 “Normal” 30 Digoxin 3-8 
Patient 6 AFL 102 76 38 Beta-Blocker, 
digoxin 
4 
Patient 7 AF 156 “Slightly 
depressed
” 
27 Digoxin, 
verapamil 
15 
Patient 21 AFL 144 71 31 Beta-Blocker 7 
Patient 27 AF 100 55 41 Digoxin, 
verapamil 
3 
Patient 29 AF 133 71 47 Beta-Blocker, 
amiodarone 
11 
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TABLE 6:  
Pre and post-treatment echocardiographic parameters of pure and impure TIC  
 
 Pure TIC 
At 
presentation 
(n=33)  
Pure TIC 
Post-
treatment 
(n=33) 
P value ∫  Impure TIC 
At 
presentation 
(n=12) 
Impure TIC 
Post-
treatment 
(n=12) 
P value ∫ 
LVEF  (%) 32.4+/-9.5 53.2+/-10.5 <0.001 29.2+/-10.0 55.0+/-9.9 <0.001 
LVIDd (cm) 5.7+/-0.7 5.3+/-0.8 0.004 5.7+/-1.0 5.5+/-0.8 0.86 
LVIDs (cm) 4.8+/-0.8 3.6(2.2-4.6) 0.001 ¶ 4.8+/-0.8 3.8(2.7-4.4) 0.04 ¶ 
LA size (cm) 4.2+/-1.0 4.1+/-0.8 0.19 4.81+/-1.5 4.7+/-1.3 0.92 
 
∫ T-test  
¶ Mann-Whitney Test 
 
 
 
 
 
 
 
 
 
 
 
 
 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
TABLE 7:  
Pure TIC patients with lenient heart rate control and late improvement of left 
ventricular function 
 
Patient 
(no.) 
Average resting heart rate 
on treatment (bpm) 
Patient 33 111 
Patient 1 92 
Patient 15 100 
Patient 4 96 
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TABLE 8:  
Post-treatment echocardiographic parameters of pure TIC patients with complete LV  
improvement and normal controls matched for age and LVEF  
 
 Pure TIC group 
(n=17) 
Normal Controls  
(n=17) 
P value ∫ 
LVEF (%) 58.9+/-8.9 60.4+/-9.2 0.5 
LVIDd (cm) 5.2+/-0.6 4.8+/-0.5 0.06 
LVIDs (cm) 3.5+/-0.5 3.2+/-0.6 0.18 
LA size (cm) 4.2 +/- 0.7 3.9 +/-0.5 0.19 
 
∫ T-test  
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TABLE 9:  
Comparison of pure TIC patients with complete versus partial LV improvement 
 
 
 
Pure TIC group with 
complete LV improvement 
(LVEF >=50%) 
(n=22) 
Pure TIC group with 
partial LV improvement  
(LVEF <50%) 
(n=10) 
P value * 
Age 49.4+/-14.7 44.1+/-19.6 0.40 ¶ 
Sex       
   Male 
   Female 
 
17 (77.3%) 
5 (22.7%) 
 
7 (70.0%) 
3 (30.0%) 
0.66 
NYHA   
   NYHA I, II 
   NYHA III, IV 
   Unknown 
 
7 (31.8%) 
15 (68.2) 
0 (0.0%) 
 
3 (30.0%) 
5 (50.0%) 
2 (20.0%) 
0.77 
Palpitations    
   Yes 
   No 
   Unknown 
 
20 (90.9%) 
2 (9.1%)  
0 (0.0%) 
 
6 (60.0%) 
3 (30.0%) 
1 (10.0%) 
0.085 
Signs of heart 
failure   
  Yes 
  No 
 
9 (40.9%) 
13 (59.1%) 
 
5 (50.0%) 
5 (50.0%) 
0.631 
Sinus Rhythm  
  Yes 
  No 
  Unknown 
 
4 (18.2%) 
18 (81.8%) 
0 (0.0%) 
 
2 (20.0%) 
7 (70.0%) 
1 (10.0%) 
0.80 
LA enlargement 
  Yes 
  No 
  Unable to   
  assess 
 
6 (27.3%) 
6 (27.3%) 
10 (45.6%)  
 
3 (30.0%) 
3 (30.0%) 
4 (40.0%) 
0.62 
Q waves 
   Yes 
 
0 (0.0%) 
 
1 (10.0%) 
0.112 
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   No 
   Unknown 
22 (100.0%) 
0 (0.0%) 
8 (80.0%) 
1 (10.0%) 
LBBB 
  Yes 
  No   
  Unknown 
 
2 (9.1%) 
20 (91.9%) 
0 (0.0%) 
 
1 (10.0%) 
8 (80.0%) 
1 (10.0%) 
0.88 
RBBB 
   Yes 
   No 
   Unknown 
 
1 (4.5%) 
21 (95.5%) 
0 (0.0%) 
 
0 (0.0%) 
9 (90.0%) 
1 (10.0%) 
0.52 
LVH 
  Yes 
  No 
  Unknown 
 
4 (18.2%) 
18 (81.8%) 
0 (0.0%) 
 
4 (40.0%) 
5 (50.0%) 
1 (10.0%) 
0.13 
Repolarization 
abnormalities  
  Yes 
  No 
  Unknown 
 
 
11 (50.0%) 
11 (50.0%) 
0 (0.0%) 
 
 
6 (60.0%) 
3 (30.0%) 
1 (10.0%) 
0.40 
QRS width (ms) 90.2+/-12.9 106+/-28.5 0.04 ∫ 
LVEF (%) 33.8+/-10.3 30.7+/-7.3 0.41 ∫ 
LVIDd (cm) 5.7+/-0.7 5.7+/-0.8 0.97 ∫ 
LVIDs (cm) 4.8+/-0.9 4.9+/-0.7 0.83 ∫ 
LA size (cm) 4.1+/-1.4 4.3+/-0.6 0.71 ∫ 
 
¶ Mann-Whitney Test 
* Chi-Square Test 
∫  T-test 
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TABLE 10:  
Causes of TIC 
 
 
Supraventricular 
 
Atrial fibrillation 
Atrial flutter 
Atrial tachycardia 
Atrio-ventricular nodal re-entry tachycardia 
Atrio-ventricular re-entry tachycardia 
Inappropriate sinus tachycardia 
Permanent junctional reciprocating tachycardia 
 
Ventricular 
 
Right ventricular outflow tract tachycardia 
Fascicular tachycardia 
Bundle branch re-entry tachycardia 
 
Ectopy 
 
Premature ventricular ectopics 
 
Pacing 
 
Rapid atrial or ventricular pacing 
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GRAPHS 
 
GRAPH 1  
The ROC curve analysis of LVIDd dimensions according to LVEF in the TIC and DCMO 
groups 
   
 
 
 
 
 
 
 
 
 
 
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
S
e
n
s
it
iv
it
y
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.1989
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
GRAPH 2  
The ROC curve analysis of QRS duration according to LVEF in the TIC and DCMO groups 
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GRAPH 3:  
Group A (Early recovery) 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
Presentation 3-6 months Last available
LV
EF
 (
%
)
Time
Patient 24
Patient 12
Patient 16
Patient 30
Patient 21
Patient 11
Patient 19
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
GRAPH 4:  
Group B (Late recovery) 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
Presentation 6-12 months Last available
LV
EF
 (
%
)
Time
Patient 33
Patient 22
Patient 1
Patient 4
Patient 15
Patient 17
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
GRAPH 5: 
Scatterplot of LV dimensions at presentation and last available follow-up 
 
Scatterplot: LVIDd1   vs. LVIDd2   (Casewise MD deletion)
LVIDd2   = 1.3669 + .68205 * LVIDd1
Correlation: r = 0.68, p=0.002
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